Asahi Kasei will acquire Germany’s Aicuris for €780 million (~$919 million) to expand into severe infectious diseases. The deal adds pritelivir and AIC468 to its transplant and nephrology-focused portfolio and includes royalty income from Prevymis. Expected to close in fiscal Q1 2026, the acquisition supports its goal of ¥300 billion (~$1.92 billion) pharma sales and 15 per cent margin by 2030.